Background. Approximately 3% of children are born small for gestational age (SGA), and ϳ10% of SGA children maintain a small body size throughout childhood and often into adult life. Among short SGA children, growth hormone (GH) therapy increases shortterm growth in a dose-dependent manner; experience with long-term therapy is limited.
B
y definition, ϳ3% of children are born small for gestational age (SGA) (SD score [SDS] below Ϫ2 for weight and/or length at preterm or term birth). Most SGA infants exhibit sufficient postnatal catch-up growth to normalize their stature by the age of 2 years, regardless of whether they were born preterm or at term. 1 Approximately 10% of SGA children maintain a small body size, defined as a height below Ϫ2 SD throughout childhood; among adults with short stature, ϳ20% were born SGA. 2 Growth hormone (GH) therapy, if started in middle childhood, increases short-term growth (over 1-5 years) in a dose-dependent manner. [3] [4] [5] [6] [7] [8] [9] However, short-term bone maturation also accelerates in a dose-dependent manner; therefore, height gain into adulthood was long anticipated to be less dose dependent than height gain in childhood. 5 This anticipation was corroborated by the first results with long-term GH therapy (ϳ33 or ϳ67 g/kg per day for 7-8 years, starting at ϳ8 years of age), which indicated not only that GH therapy is effective in increasing adult height but also that the dose dependency, if any, amounts to no more than ϳ0.3 SD when adult height is reached. 10 The current consensus is that more adult height results are needed before recommendations regarding short-and longterm GH doses can be made. 11, 12 Here we report an epianalysis (based on individual data) of the first adult height results for SGA children who were enrolled in 3 randomized studies comparing the long-term growth-promoting efficacy of 2 GH doses (33 or 67 g/kg per day for ϳ10 years; starting at ϳ5 years of age). In addition, we report a meta-analysis (based on group data) of the previous 10 and present results on adult height; the addition of statistical power allowed us to delineate more clearly the limited dose dependency of the GH-induced gain in the adult height of short SGA children.
METHODS

Study Population and Design
In 1990, 3 randomized, multicenter studies were initiated to explore the effects of continuous GH treatment among non-GHdeficient SGA children who had failed to normalize their stature through spontaneous catch-up growth during infancy. The originally enrolled study populations in the Nordic countries (Denmark, Finland, Norway, and Sweden), Germany, and France (234 treated) were described in reports of the results after 2, 4, and 6 years of GH therapy. [5] [6] [7] The inclusion criteria were as follows: (1) birth weight or length below Ϫ2 SD for gestational age, (2) height below Ϫ2 SD for chronologic age, (3) height velocity below 0 SD (France) or ϩ1 SD (Germany and Nordic countries) for chronologic age, (4) chronologic age between 2 and 8 years (2-7 years for German girls and 2-9 years for Nordic boys), (5) prepubertal condition at the start of the study, (6) serum GH concentration of Ͼ10 g/L in a random sample or after a GH stimulation test, and (7) written informed consent. The exclusion criteria were as follows: (1) endocrine or chronic disease; (2) previous or ongoing chemotherapy, radiotherapy, or GH or anabolic steroid treatment; or (3) chromosomal anomaly, skeletal dysplasia, severe mental retardation, or malformation syndrome, except for Silver-Russell, fetal alcohol, and Dubowitz syndromes (exceptions not applicable to France and Nordic countries).
Each of these 3 studies was originally designed as an openlabel, controlled, multicenter trial over 2 years with 3 parallel groups assembled through weighed randomization. [3] [4] [5] [6] [7] One group was not treated and 2 groups were treated with daily subcutaneous injections of human GH (Genotropin; Pfizer, Stockholm, Sweden), given at a dose of 33 or 67 g/kg. None of the untreated control groups was maintained beyond 2 years of study. 7 After the initial 2 years, the Nordic and German studies investigated the effects of continued GH treatment at a daily dose of 33 or 67 g/kg. In France, continuous GH treatment at a daily dose of 33 or 67 g/kg was available only to children who had failed to reach a height above Ϫ1 SD, irrespective of mid-parental height. 7 Because of this study design in France, the adult height results obtained with continuous GH treatment in that trial were anticipated to be biased toward poor responsiveness, and they were taken into account only for the assessment of the dose dependency of gain in adult height.
In the present epianalysis, the additional criteria for inclusion were as follows: (1) end-pubertal growth velocity of Ͻ4 cm/year and (2) continuous GH treatment for Ն7.0 years. Table 1 lists the additional exclusion criteria that ultimately defined the present study population (n ϭ 28).
Study Methods
Study visits, including auxologic evaluations and dose adjustments, were scheduled at least every 6 months. The effects of GH administration on growth were assessed by determining changes in variables such as weight and height SDS, with and without adjustment for mid-parental height SDS, as described. 7 The onset of puberty was defined for girls as breast stage of Ն2 and for boys as testicular volume of Ն4 mL.
The true gain in adult height is not known for the children in this study population, in part because we included children with ongoing growth at a rate of up to 4 cm/year at the last recorded visit. The estimated gain in adult height was calculated as the difference between the height SD for adult normative values (using the upper reference age of 21 years 13 ) at the last recorded visit and the height SD for chronologic age at the start of treatment. To facilitate interpretation of the results, the gain in height SD was also converted into centimeters.
Initially, we analyzed the change in height SD for chronologic age from the start of treatment to the last recorded visit. This analysis, however, overestimated the true gain in adult height, because children had reached near-adult height without necessarily reaching adult age. Because adult height had not yet been reached by all children, the uniform use of height SD for adult normative values underestimated the change in height SD. Nevertheless, we used the latter normative values to compensate for not taking into account the spontaneous catch-up growth (an average of 0.3-0.4 SD) that short SGA children are expected to exhibit if they remain untreated. 10, [14] [15] [16] [17] [18] [19] The French, German, and Nordic protocols specified 3 childhood height references, which had different adult-age criteria. In this analysis, we used only 1 of these references, 13 to harmonize the data from the 3 trials.
Statistical Analyses
The gain in adult height was analyzed with multivariate linear regression analyses. The analysis of covariance (ANCOVA) model included country (France, Germany, or Nordic countries) and GH dose as factors and height SD at the start of the study as a covariate. Other variables were presumed to have effects on the gain in adult height but they showed no detectable effect in this population (chronologic age at the start of GH therapy, percentage of time receiving GH therapy, and target height SD) or data were not available for all children (bone age delay at the start of GH therapy); therefore, these variables were excluded from the full model, to yield more degrees of freedom.
To increase statistical power in the analysis of dose dependency, we performed a meta-analysis that included the results from another randomized study, which used Norditropin (Novo 10.4 (7.6, 12.4) e460 LONG-TERM GROWTH OF SGA CHILDREN WITH GH Nordisk, Bagsvaerd, Denmark). 10 In the latter study, adult height was reached by almost all children, another height reference was used, 20 and the gain in adult height was estimated from the change in height SD for chronologic age between GH treatment start and the last recorded visit; in other words, adult height was not assessed with adult normative values. That study was analyzed with both a 2-sample t test and an ANCOVA, with the t test analysis being presented as the main analysis. The results from the t test were used in the meta-analysis, combined with the ANCOVA results from the Nordic, German, and French trials.
In the meta-analysis, differences and SE values were combined into a weighed average. 21 Table 2 displays the clinical and treatment characteristics of the study population. At the start of treatment, the mean age of the children was ϳ5 years and their height was Ͼ3 SD below the normative value for chronologic age; after adjustment for mid-parental height, their height was still Ͼ2 SD below the normative value. The average duration of GH treatment was ϳ10 years. At the last recorded visit, the mean growth velocity was 1.6 cm/year. In the highdose group, the GH amount given was ϳ10% below the intended study dose, partly because of underestimation of weight gain between study visits. Table 3 displays the results of an ANCOVA of the increase in height SDS between the start of GH treatment and the last visit. The model accounts for 60% of the observed variance; shorter children gained more height. In France, the apparently lower efficacy of continuous GH therapy is likely attributable to the bias introduced by the study design. Table 4 summarizes the long-term results, as well as the meta-analysis of the dose effect on the increase in height SDS between the start of GH treatment and the last visit. The outcomes among Nordic, German, and French children (n ϭ 28) suggested that adult height increased more with the higher-dose regimen, compared with the lower-dose regimen. In the metaanalysis, the higher-dose regimen was confirmed to elicit a long-term height gain that was superior to that achieved with the lower-dose regimen by a mean of 0.4 SD (ϳ1 inch, P ϭ .019).
RESULTS
DISCUSSION
In the absence of randomized, control groups up to adult height, 7 we estimated the GH-induced gain in the adult height of short SGA children by calculating the difference between height SDS at the start of GH therapy and at the last visit. This approach allowed us to estimate that long-term (ϳ10-year) GH therapy reduced the adult height deficit of short SGA children; the long-term benefit proved less dose depen- dent than the short-term growth acceleration evoked by GH therapy. These long-term findings were well in line not only with the short-term findings for the same cohorts 5-8 but also with long-term findings for another cohort of SGA children who received similar GH doses in a comparable age range. 9, 10 Inevitably, the first adult height results for any long-term SGA cohort are biased toward those for children who started GH hormone therapy late and/or completed puberty early. Whether this bias resulted in an underestimation of the efficacy of GH in the present analysis will ultimately need to be clarified by adding to the present results those of early GH starters and/or late maturers. Shorter stature at the start of GH treatment was associated with more long-term height gain. Therefore, the most height gain was observed for the children who needed it most, as judged by their shortness of stature. Recently, the short-term growth response to GH among short SGA children was found to be higher for children with relatively low somatotropic activity and relatively high insulin sensitivity. 22, 23 Because pretreatment somatotropic activity and insulin sensitivity were not necessarily screened in the present studies, it remains to be determined to what extent a low height SDS at baseline reflects low somatotropic activity or an insulinsensitive state among short SGA children.
CONCLUSIONS
Our findings confirm that GH therapy is an effective and safe approach to reduce the adult height deficit that short SGA children otherwise face; in addition, they confirm that height gain is less dose dependent over the long term than over the short term, at least within the dose range explored to date. For SGA children whose stature is not extremely short (for example, height above Ϫ3 SD), current data support the use of a GH dose of ϳ33 g/kg per day from start to adult height, particularly if treatment is started at a young age (4 -6 years). Shorter children (height below Ϫ3 SD) might benefit from an approach in which short-term catch-up growth is achieved with a higher dose (Ն50 g/kg per day) and long-term growth up to adult height is ensured with a GH dose of ϳ33 g/kg per day. Because GH-induced accelerations of height and weight gain evolve in parallel, 5 dose tapering from Ն50 mg/kg to ϳ33 g/kg can be accomplished by simply maintaining the absolute GH dose (in micrograms) while the child gains weight (in kilograms). With this algorithm, more growth-responsive children taper their GH doses more quickly down to ϳ33 g/kg per day.
